Biologic Drugs and Medicare Price Negotiation
T
Thomas J. Hwang
(Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston)
N
Nancy L. Keating
(Department of Health Care Policy, Harvard Medical School, Boston)
S
Stacie B. Dusetzina
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 393, Issue 1
Published
July 03, 2025
Pages
6-9
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (3)
T
Thomas J. Hwang
Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston
N
Nancy L. Keating
Department of Health Care Policy, Harvard Medical School, Boston
S
Stacie B. Dusetzina
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582